Prestige Consumer Healthcare Inc. (NYSE:PBH) Stock Holdings Decreased by American Century Companies Inc.

Posted by on Jun 9th, 2023

American Century Companies Inc. reduced its position in Prestige Consumer Healthcare Inc. (NYSE:PBH – Get Rating) by 10.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 234,233 shares of the company’s stock after selling 25,911 shares during the period. American Century Companies Inc. owned about 0.47% of Prestige Consumer Healthcare worth $14,663,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. BlackRock Inc. boosted its holdings in shares of Prestige Consumer Healthcare by 12.4% during the first quarter. BlackRock Inc. now owns 9,115,718 shares of the company’s stock worth $482,584,000 after purchasing an additional 1,004,337 shares during the period. Nordea Investment Management AB boosted its holdings in shares of Prestige Consumer Healthcare by 72.1% during the fourth quarter. Nordea Investment Management AB now owns 1,030,901 shares of the company’s stock worth $65,277,000 after purchasing an additional 431,813 shares during the period. Nuveen Asset Management LLC boosted its holdings in shares of Prestige Consumer Healthcare by 27.5% during the third quarter. Nuveen Asset Management LLC now owns 743,891 shares of the company’s stock worth $37,068,000 after purchasing an additional 160,673 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Prestige Consumer Healthcare by 3.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,674,930 shares of the company’s stock worth $230,053,000 after purchasing an additional 116,613 shares during the period. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of Prestige Consumer Healthcare by 14.6% during the first quarter. Goldman Sachs Group Inc. now owns 805,044 shares of the company’s stock worth $42,619,000 after purchasing an additional 102,602 shares during the period. 99.98% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. TheStreet cut shares of Prestige Consumer Healthcare from a “b+” rating to a “c+” rating in a report on Thursday, May 4th. Royal Bank of Canada reduced their target price on shares of Prestige Consumer Healthcare from $107.00 to $104.00 and set a “sector perform” rating for the company in a research note on Friday, March 17th. Oppenheimer reduced their target price on shares of Prestige Consumer Healthcare from $72.00 to $71.00 and set an “outperform” rating for the company in a research note on Friday, February 17th. Finally, StockNews.com assumed coverage on shares of Prestige Consumer Healthcare in a research note on Thursday, May 18th. They issued a “buy” rating for the company. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $79.25.

Prestige Consumer Healthcare Price Performance

Shares of Prestige Consumer Healthcare stock opened at $58.25 on Friday. Prestige Consumer Healthcare Inc. has a 1-year low of $48.51 and a 1-year high of $67.45. The firm has a fifty day simple moving average of $60.59 and a 200-day simple moving average of $61.62. The stock has a market capitalization of $2.89 billion, a price-to-earnings ratio of -34.67, a PEG ratio of 1.69 and a beta of 0.55. The company has a current ratio of 2.44, a quick ratio of 1.43 and a debt-to-equity ratio of 0.93.

Prestige Consumer Healthcare (NYSE:PBH – Get Rating) last announced its earnings results on Thursday, May 4th. The company reported $1.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.04 by $0.03. Prestige Consumer Healthcare had a negative net margin of 7.30% and a positive return on equity of 13.38%. The business had revenue of $285.90 million for the quarter, compared to analyst estimates of $280.58 million. During the same quarter in the previous year, the firm posted $0.91 earnings per share. Prestige Consumer Healthcare’s revenue was up 7.1% compared to the same quarter last year. On average, sell-side analysts expect that Prestige Consumer Healthcare Inc. will post 4.3 earnings per share for the current year.

Prestige Consumer Healthcare Company Profile

(Get Rating)

Prestige Consumer Healthcare, Inc engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the following segments: North American OTC Healthcare and International OTC Healthcare. The North American and International OTC Healthcare segments manages the following brands: BC/Goody’s, Beano, Boudreaux’s Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden’s, Monistat, Nix, Pedia-Lax, and Summer’s Eve.

Featured Articles

Institutional Ownership by Quarter for Prestige Consumer Healthcare (NYSE:PBH)

Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.